ECM
VIR icon

Everence Capital Management’s Vir Biotechnology VIR Stock Holding History

Everence Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,780
Closed -$96K – 1039
2024
Q3 		$96K Sell
12,780
-8,650
-40% -$75.1K 0.01% 744
2024
Q2 		$181K Hold
21,430
– – 0.01% 697
2024
Q1 		$217K Hold
21,430
– – 0.01% 689
2023
Q4 		$216K Hold
21,430
– – 0.02% 679
2023
Q3 		$201K Buy
21,430
+11,260
+111% +$161K 0.02% 674
2023
Q2 		$271K Hold
10,170
– – 0.02% 560
2023
Q1 		$237K Hold
10,170
– – 0.02% 622
2022
Q4 		$257K Hold
10,170
– – 0.02% 595
2022
Q3 		$196K Hold
10,170
– – 0.02% 660
2022
Q2 		$259K Buy
+10,170
New +$237K 0.02% 562

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Everence Capital Management's VIR Position: Q4 2024 in Review

Everence Capital Management sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 12,780 shares — an estimated $96K sold.

Everence Capital Management first reported a position in VIR in Q2 2022 and held it in 10 quarters. The position peaked at $271K in Q2 2023. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Everence Capital Management reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Everence Capital Management sold 12,780 Vir Biotechnology shares in Q4 2024, an estimated $96K.
  • Everence Capital Management first reported a position in Vir Biotechnology in Q2 2022 and held it in 10 quarters.
  • Everence Capital Management's Vir Biotechnology position peaked at $271K in Q2 2023.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Everence Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.